Evidence map›Paper›PMID 35246933›Full record

ReviewLiver international : official journal of the International Association for the Study of the Liver2022

Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases.

Maria Stella Franzè, Teresa Pollicino, Giovanni Raimondo, Giovanni Squadrito

Open access · hybridAbstract readReview
In one paragraph

Review in Liver international : official journal of the International Association for the Study of the Liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Occult hepatitis B virus infection.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maria Stella FranzèDepartment of Clinical and Experimental Medicine, Messina University, Messina, Italy.ORCID 0000-0002-9815-5275
Teresa PollicinoDepartment of Human Pathology, Messina University, Messina, Italy.ORCID 0000-0001-6602-3035
Giovanni RaimondoDepartment of Clinical and Experimental Medicine, Messina University, Messina, Italy.ORCID 0000-0003-3112-8587
Giovanni SquadritoDepartment of Clinical and Experimental Medicine, Messina University, Messina, Italy.ORCID 0000-0003-0508-4816
University of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data concerning the prevalence of hepatitis B virus (HBV) occult infection (OBI) varies greatly in the different studies according to the sensitivity and specificity of the diagnostic approaches and the HBV prevalence in the different populations examined. The clinical implications of OBI are still debated. While the impact of OBI in HBV transmission as well as in HBV reactivation under immunosuppression are well established, the role of OBI in liver disease and hepatocellular carcinoma (HCC) development are still not definitively elucidated. It has been hypothesized that OBI might contribute to worsening the liver disease course when other causes of liver damage co-exist. Furthermore, much evidence suggests a role of OBI in the hepato-carcinogenesis processes through both indirect and direct oncogenic mechanisms that might favour HCC development. Data on the OBI clinical implications mainly come from studies performed in patients with hepatitis C virus (HCV) infection. However, HCV prevalence has dramatically fallen in the past years also because of the advent of specific and highly effective direct acting antivirals, with a consequent abrupt change of the worldwide scenario of chronic liver disease. Information about OBI prevalence and possible clinical impact in non-HCV-related liver disease are fragmentary, and the objective of this review is to critically summarize the available data in this field.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis B, ChronicHepatitis CHepatitis C, ChronicLiver NeoplasmsAntiviral AgentsCarcinogenesisDNA, ViralHepacivirusHepatitis B Surface AntigensHepatitis B virusHumansAntiviral AgentsDNA, ViralHepatitis B Surface AntigenscirrhosisHCV-negative chronic liver diseasehepatocellular carcinomaintrahepatic cholangiocarcinomaoccult hepatitis B infection

Identifiers

PMID35246933
PMCPMC9310828
OpenAlexW4220771797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.